Lupin Ends 2018 On High, Strikes Large MALT1 Deal With AbbVie

 
• By Anju Ghangurde

AbbVie has in-licensed Lupin’s MALT1 (mucosa-associated lymphoid tissue lymphoma translocation protein 1) inhibitor program for over $900m in potential milestone payments, bringing Christmas cheer for the Indian firm. The deal terms for the preclinical asset are rather striking.

Skydivers
LUPIN HAS LICENSED ITS EARLY STAGE ONCOLOGY ASSET TO ABBVIE

Lupin Ltd., which has had a generally tough run in 2018, is ending the year with a bang, striking a licensing deal that is potentially valued at over $900m with AbbVie Inc. for an early stage asset.(Also see "Lupin Paints Better Second Half Riding On Solosec, New US Launch Hopes" - Scrip, 2 November, 2018.)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip